Enhance reflects limited population.
I treat my patients to goal numbers. The ENHANCE study only shows me that in an unfortunate genetic group, not treating to goal does not result in any benefit ("Next Steps on Ezetimibe, If Any, May Take Months," Feb. 15, 2008, p. 4).
The study does nothing for my average patient except to push me to maximize statin dose and add ezetimibe when goals are not met. I am concerned that so many patients using statins are discouraged by the study and react only to the general information that cholesterol drugs do not work.
Richard Raborn, M.D.
Boynton Beach, Fla.
![]() ![]() ![]() ![]() | |
Title Annotation: | Letters |
---|---|
Author: | Raborn, Richard |
Publication: | Family Practice News |
Article Type: | Letter to the editor |
Date: | Jun 1, 2008 |
Words: | 101 |
Previous Article: | A Doctor's take on legal issues. |
Next Article: | Challenge of hematologic cancer DX. |